Shots:
- Madrigal has entered into an exclusive global license agreement with Suzhou Ribo Life Science & its subsidiary Ribocure Pharmaceuticals for 6 preclinical siRNA programs in metabolic dysfunction-associated steatohepatitis (MASH)
- The deal allows Madrigal to pair a targeted gene-silencing siRNA approach with Rezdiffra to assess whether genetically reducing disease drivers can enhance its therapeutic impact, with IND-enabling activities for initial assets set to begin in 2026
- As per the deal, Madrigal will gain an exclusive global license to develop, manufacture & commercialize 6 siRNA candidates, while Ribo will receive $60M upfront & is eligible for ~$4.4B in cumulative milestone payments across the programs, plus royalties on net sales
Ref: Globenewswire | Image: Madrigal & Ribo |Press Release
Related News: Madrigal Pharmaceuticals Broadens MASH Pipeline with Pfizer’s Ervogastat Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
